Shopping Cart
Remove All
Your shopping cart is currently empty
JAK-IN-23 is an orally active dual JAK/STAT and NF-κB inhibitor that inhibits JAK1 (IC50: 8.9 nM), JAK2 (IC50: 15 nM), and JAK3 (IC50: 46.2 nM). It exhibits strong anti-inflammatory effects and can reduce the release of various pro-inflammatory factors. JAK-IN-23 can be used to study inflammatory bowel disease (IBD).
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $916 | 10-14 weeks | 10-14 weeks | |
| 50 mg | $1,190 | 10-14 weeks | 10-14 weeks | |
| 100 mg | $1,860 | 10-14 weeks | 10-14 weeks |
| Description | JAK-IN-23 is an orally active dual JAK/STAT and NF-κB inhibitor that inhibits JAK1 (IC50: 8.9 nM), JAK2 (IC50: 15 nM), and JAK3 (IC50: 46.2 nM). It exhibits strong anti-inflammatory effects and can reduce the release of various pro-inflammatory factors. JAK-IN-23 can be used to study inflammatory bowel disease (IBD). |
| Targets&IC50 | ISG (interferon-stimulated gene):3.3 nM, JAK3:46.2 nM, JAK2:15 nM, NF-κB:150.7 nM, JAK1:8.9 nM |
| Molecular Weight | 441.35 |
| Formula | C23H22Cl2N4O |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.